Does Semaglutide Reduce Heart Failure Risk Regardless of Heart Pump Strength?
Semaglutide significantly reduced cardiovascular mortality by 26% in obese heart failure patients, with benefits seen in reduced ejection fraction.
Quick Facts
What This Study Found
Semaglutide reduced cardiovascular mortality by 26% overall (RR 0.74), with a 34% reduction in HFrEF patients.
Key Numbers
- 5 RCTs, 6,898 total patients
- Cardiovascular death: 26% reduction (RR 0.74, 95% CI 0.58-0.94, p=0.02)
- HFrEF subgroup: 34% reduction (RR 0.66, p=0.01)
- HFpEF subgroup: 16% reduction (RR 0.84, p=0.37, not significant)
- Quality of life (KCCQ-CSS): improved by 7.72 points (p<0.001)
- 6-minute walk distance: improved by 14.83 meters (p=0.006)
How They Did This
Meta-analysis of 5 randomized controlled trials totaling 6,898 patients, with subgroup analysis by ejection fraction.
Why This Research Matters
This is among the first evidence that GLP-1 receptor agonists may directly reduce cardiovascular death in heart failure patients, not just improve symptoms.
The Bigger Picture
If confirmed, semaglutide could become a game-changing heart failure therapy, addressing both the obesity driver and cardiovascular outcomes.
What This Study Doesn't Tell Us
Meta-analysis with heterogeneous trial designs. HFpEF benefit did not reach significance. Relatively short follow-up in some trials.
Questions This Raises
- ?Will larger HFpEF-specific trials confirm the mortality benefit?
- ?Is the heart failure benefit independent of weight loss?
Trust & Context
- Key Stat:
- 26% Reduction in cardiovascular mortality with semaglutide vs. placebo in obese HF patients
- Evidence Grade:
- Meta-analysis of 5 RCTs provides moderately strong evidence. Individual trial sizes and designs vary.
- Study Age:
- Published in 2025 with trials through August 2024.
- Original Title:
- Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.
- Published In:
- Cardiology in review (2025)
- Authors:
- Otmani, Zina, Elsayed, Hazem Ayman, Yassin, Mazen Negmeldin Aly, Saihi, Mohamed Jalil, Aldemerdash, Mohamed A, Alzawahreh, Ahmad, Hassan, Amr, Alahmed, Farouq Bahaa, Gonnah, Ahmed R, Abdelaziz, Ahmed
- Database ID:
- RPEP-12893
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Can semaglutide help heart failure patients?
This meta-analysis suggests semaglutide may reduce cardiovascular death by 26% in obese heart failure patients and improve symptoms and exercise capacity.
Does the benefit depend on heart pump strength?
The mortality benefit was statistically significant only in patients with reduced ejection fraction. Results in preserved ejection fraction were promising but not conclusive.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-12893APA
Otmani, Zina; Elsayed, Hazem Ayman; Yassin, Mazen Negmeldin Aly; Saihi, Mohamed Jalil; Aldemerdash, Mohamed A; Alzawahreh, Ahmad; Hassan, Amr; Alahmed, Farouq Bahaa; Gonnah, Ahmed R; Abdelaziz, Ahmed. (2025). Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.. Cardiology in review. https://doi.org/10.1097/CRD.0000000000000925
MLA
Otmani, Zina, et al. "Semaglutide in Patients with Obesity and Heart Failure Irrespective of Their Baseline Ejection Fraction: An Efficacy and Safety Meta-analysis of Randomized Controlled Trials.." Cardiology in review, 2025. https://doi.org/10.1097/CRD.0000000000000925
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide in Patients with Obesity and Heart Failure Irres..." RPEP-12893. Retrieved from https://rethinkpeptides.com/research/otmani-2025-semaglutide-in-patients-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.